Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12518MR)

This product GTTS-WQ12518MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12518MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11857MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ3183MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ8569MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ4435MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ9523MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ10475MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ5908MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ11914MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW